Compare NREF & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NREF | AVIR |
|---|---|---|
| Founded | 2019 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medicinal Chemicals and Botanical Products |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 298.0M | 334.5M |
| IPO Year | N/A | 2020 |
| Metric | NREF | AVIR |
|---|---|---|
| Price | $11.24 | $4.14 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $14.50 | $9.00 |
| AVG Volume (30 Days) | 66.3K | ★ 275.9K |
| Earning Date | 11-05-2026 | 11-09-2026 |
| Dividend Yield | ★ 16.30% | N/A |
| EPS Growth | N/A | ★ 3.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $351,367,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.05 | N/A |
| P/E Ratio | $4.78 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.16 | $2.93 |
| 52 Week High | $18.43 | $6.45 |
| Indicator | NREF | AVIR |
|---|---|---|
| Relative Strength Index (RSI) | 20.74 | 41.48 |
| Support Level | N/A | $4.06 |
| Resistance Level | $16.04 | $4.54 |
| Average True Range (ATR) | 0.68 | 0.24 |
| MACD | -0.27 | 0.03 |
| Stochastic Oscillator | 2.47 | 38.74 |
NexPoint Real Estate Finance Inc is a commercial mortgage REIT focused on generating attractive, risk-adjusted returns for shareholders over the long term. The company invests mainly in first-lien mortgage loans, mezzanine loans, preferred equity, multifamily properties, and common equity investments, as well as multifamily and single-family rental CMBS securitizations, promissory notes, revolving credit facilities, and stock warrants. It focuses on real estate sectors where its management has operating expertise, including multifamily, single-family rental, self-storage, industrial, and life sciences, mainly in top metropolitan areas.
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.